On July 15, Defense Secretary Pete Hegseth announced that the U.S. military will begin screening every service member over the age of 30 for low testosterone, and will offer testosterone replacement therapy — TRT, a long-term course of the hormone — to anyone who comes up short. He posted the news to X over the caption “The High-T Department of War,” and described the program in a video as “not about artificial enhancement” but about “restoring and optimizing your natural capabilities.”
The same administration threw transgender people out of the armed forces and spent the last year and a half calling hormone therapy a dangerous ideology with no place in the ranks. In January 2025, one executive order — 14183 — barred people with a history of gender dysphoria from serving. A day later, a second order, 14187, labeled puberty blockers and sex hormones “chemical and surgical mutilation,” and named testosterone specifically as mutilation when it is used “to align an individual’s physical appearance with an identity that differs from his or her sex.”
Eighteen months later, the Pentagon is building a program to find the men who don’t have enough of that same hormone and give them more of it.
The testosterone in a colonel’s prescription and the testosterone a transgender man takes are the same molecule. Not similar. Identical. The Endocrine Society — the professional body that writes the clinical guidelines — puts patients on the same drug, in the same forms, the injection and the gel and the patch, with the same yearly bloodwork, whether the person is a fifty-year-old with a documented deficiency or a trans man starting his transition. A pharmacist filling the two prescriptions could not tell them apart. The only thing that differs is whose name is on the bottle.
Which is the whole story, and everyone can see it. Hegseth’s own pitch for the program — restoring and optimizing your natural capabilities — is, almost word for word, the case that transgender people and their doctors have made for gender-affirming care for as long as the phrase has existed.
Representative Pramila Jayapal, the Washington Democrat and the mother of a transgender child, said it without decoration: “This is gender-affirming care, and it completely debunks all of Republicans’ attacks on trans people.” Senator Tammy Duckworth, the Illinois Democrat and Army veteran who lost both legs when her Black Hawk was shot down over Iraq, was shorter about it: “Sounds like gender-affirming care to me.”
Transgender service members were forced out under the ban and cut off from the exact hormones their own military doctors had been prescribing them. Now those same doctors have been told to start writing that prescription for everybody else.
The response from the right has been to laugh at the Democrats pointing this out rather than answer them — Fox News ran a piece on Democrats getting “roasted” for the comparison. What no one on that side has done is explain why the same molecule is medicine in one body and ideology in another, because there is no way to say it out loud. The strongest version of their case is that testosterone for aging troops is optimization, not transition — a different medical context. But that doesn’t move the pharmacology, and it doesn’t move the executive order, which did not outlaw a context. It outlawed a drug, by name, for a particular kind of person.
Shannon Minter, legal director of the National Center for LGBTQ Rights, put it to the New York Times: the program “makes crystal clear that the policy banning transgender troops for taking the same medication is pure bias.”
The administration has spelled the double standard out itself, in court. For more than a year, the Justice Department defended the transgender military ban partly on money, telling federal judges that transition-related care was a needless expense and pegging it at roughly $52 million across the entire department over nine years. That was the figure it called waste. The new program will screen hundreds of thousands of troops and prescribe, indefinitely, to everyone who qualifies. No one has put a price tag on that one.
And the doctors the program leans on aren’t sold on the medicine. Urologists and men’s-health specialists told TIME and the Washington Post that screening men with no symptoms is a bad idea, and that dropping testosterone into a body that makes enough of its own can shut that production down and cause infertility. The same medical establishment invoked for “readiness” thinks the protocol is questionable. The science, it turns out, settles only when the patient is right.
On the same afternoon, at the Army War College in Carlisle, Pennsylvania, President Trump told an audience that grants under the CHIPS Act — the semiconductor subsidies — had required the companies receiving them to be run by transgender people. “If you weren’t transgender, as an example, you didn’t qualify,” he said. There is no such requirement anywhere in the statute, which conditions its money on building chips inside the United States and staying out of China. So in one day the administration conjured a country where the government forces firms to install transgender executives, and stood up a real program to screen soldiers for the hormone it calls mutilation the moment a transgender person takes it.
The executive order that names testosterone as mutilation still stands. So does the ban that discharged transgender troops for taking it. And now the Pentagon will screen the rest of the force and offer that same drug to anyone who needs it — everyone except the people it was taken from.
